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Abstract
Starting from the observation that tumor necrosis
factor–related apoptosis-inducing ligand (TRAIL)/
Apo-2L protein is expressed in both malignant and
inflammatory cells in some highly vascularized soft
tissue sarcomas, the angiogenic potential of TRAIL
was investigated in a series of in vitro assays. Re-
combinant soluble TRAIL induced endothelial cell
migration and vessel tube formation to a degree
comparable to vascular endothelial growth factor
(VEGF), one of the best-characterized angiogenic
factors. However, the proangiogenic activity of TRAIL
was not mediated by endogenous expression of VEGF.
Although TRAIL potentiated VEGF-induced extracellu-
lar signal–regulated kinase (ERK) phosphorylation
and endothelial cell proliferation, the combination of
TRAIL + VEGF did not show additive effects with
respect to VEGF alone in inducing vessel tube
formation. Thus, although TRAIL has gained attention
as a potential anticancer therapeutic for its ability to
induce apoptosis in a variety of cancer cells, our
present data suggest that TRAIL might also play an
unexpected role in promoting angiogenesis, which
might have therapeutic implications.
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Introduction
Tumor necrosis factor–related apoptosis-inducing ligand
(TRAIL)/Apo-2L is a member of the TNF family of cytokines,
which is broadly expressed at the mRNA level in many
normal tissues and tumor cell lines [1]. TRAIL is a type II
membrane protein, which can be proteolytically cleaved by
cysteine proteases to a soluble form [2] as previously shown
also for TNF-a and CD95 (Apo-1/Fas) ligand. The unique
feature of TRAIL, compared to other members of the TNF
family, is its ability to induce apoptosis in a variety of
malignant cells both in vitro and in vivo, displaying minimal
or absent toxicity on normal cells and tissues [3,4].
TRAIL interacts with four high-affinity transmembrane
receptors belonging to the apoptosis-inducing TNF-R
family. TRAIL-R1 (DR4) and TRAIL-R2 (DR5) transduce apo-
ptotic signals on binding of TRAIL, whereas TRAIL-R3 (DcR1)
and TRAIL-R4 (DcR2) are homologous to DR4 and DR5 in their
cysteine-rich extracellular domain, but lack intracellular death
domain and apoptosis-inducing capability and have been pro-
posed to function as decoy receptors, protecting normal cells,
including endothelial cells, from apoptosis [5,6]. Although little
is known about possible nonapoptotic effects induced by
TRAIL, it has been shown that endothelial cells express all
TRAIL-Rs [6–8], whereas TRAIL protein is expressed in the
medial smooth cell layer of the aorta and pulmonary artery [9].
Whereas cleavage of Fas ligand from the cell surface requires
the action of zinc-dependent metalloproteases, generation of
soluble TRAIL involves the action of cysteine proteases [2].
Notably, the vessel wall is a rich source of cysteine proteases
[10], which suggests that the TRAIL/TRAIL-R system likely
plays a physiological role in vascular biology. In this respect, we
have recently demonstrated that addition of TRAIL to human
umbilical vein endothelial cells induces the rapid phosphoryla-
tion and activation of extracellular signal–regulated kinase
(ERK) and Akt [7,8]. Because these intracellular pathways
are known to be involved in endothelial cell survival, prolifera-
tion, and migration [11,12], in this study, we have investigated
whether TRAIL induced angiogenesis by using various in vitro
assays. Taking into consideration that several recent studies
have confirmed the hypothesis that tumor growth, in general, is
dependent on angiogenesis [13,14], we have also analyzed the
expression of TRAIL protein in soft tissue sarcomas because
these tumors are often highly vascularized [15].
Materials and Methods
Reagents and Cells
Recombinant histidine6-tagged TRAIL was produced in
bacteria and purified by chromatography on Ni2+ affinity resin,
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as described [7]. The concentration of TRAIL used in most
assays (10 ng/ml) was determined in preliminary dose–
response (0.1–1000 ng/ml) experiments. For neutralization
experiments, TRAIL was preincubated with TRAIL-R1-Fc
and/or TRAIL-R2-Fc chimeras, according to the supplier’s
instructions (R&D, Minneapolis, MI). Vascular endothelial
growth factor (VEGF; Peprotec, London, UK), was used at
the final concentration of 10 ng/ml. Polymyxin B (Calbio-
chem, La Jolla, CA), was used at the final concentration of
10 mg/ml. A pharmacological inhibitor of the ERK pathway
(PD98059; final concentration: 10 mM) was fromCalbiochem.
Primary human umbilical vein endothelial cells (HUVECs)
were obtained as described previously [8] and were used
between the third and sixth passages in vitro. Cells were
grown on 0.2% gelatin-coated tissue culture plates in M199
endothelial growth medium (BioWhittaker, Walkersville, MD)
supplemented with 20% fetal bovine serum (FBS), 10 mg/ml
heparin, and 50 mg/ml Endothelial Cell Growth Factor (ECGF)
(Sigma, St. Louis, MO).
Neoplastic Samples and Immunohistochemistry
Formalin-fixed and paraffin-embedded tissues of human
sarcomas were obtained from 10 surgically treated patients.
The tumors consisted of five liposarcomas, two leiomyosar-
comas, one rhabdomyosarcoma, one angiosarcoma, and
one Kaposi’s sarcoma. Immunohistochemical study was
performed on 4 mm sections using a streptavidin–biotin
complex immunoperoxidase technique with a polyclonal
anti–TRAIL antibody (Ab; clone H-257; Santa Cruz Biotech-
nology, Santa Cruz, CA). Isotype-matched irrelevant anti-
bodies, used as negative control, gave absence of
background. For the evaluation of tumor vascularization,
sections were stained with Ab anti-CD31 (clone JC/70A;
BioGenex, San Ramon, CA) and angiogenesis was quanti-
fied by assessment of microvessel density using previously
described techniques [16,17]. Briefly, the number of vessel
was counted throughout the entire core specimen in serial
sections. Consecutive per 20 high-power fields were ex-
amined, a median count per field was calculated, and a
simple high-density/low-density score was used. Microves-
sel density was analyzed blinded toward the result of the
TRAIL staining.
Cell Migration and Cell Invasion Assays
Cell migration was analyzed using a modified Boyden
chamber assay, as described previously [18], by using
24-well plates with inserts containing 8 mm pore size gelati-
nized polycarbonate membranes separating the two cham-
bers of each well (Transwell; Costar, New York, NY).
Cell invasion was investigated by using the Chemicon
Cell Invasion Assay kit (Chemicon International, Temecula,
CA) according to the manufacturer’s instruction. This assay
is performed in an invasion chamber, a 24-well tissue culture
plate with cell culture inserts containing an 8-mm pore size
polycarbonate membrane, over which a thin layer of extra-
cellular matrix (ECM) is dried.
For the assays, exponentially growing cells were harvest-
ed with trypsin, centrifuged, resuspended at 0.5 106 cells/ml
in migration buffer [M199 medium, 10 mM HEPES, pH 7.4,
and 0.5% bovine serum albumin (BSA)], and placed in the
upper compartment of the chambers. TRAIL or VEGF, used
alone or in combination, was added in the lower chambers.
After 4 hours (for the migration assay) or 48 hours (for the
invasion assay) of incubation at 37jC, cells on the upper face
of the membrane were scraped using a cotton swab and cells
on the lower face were fixed and stained with Mayer’s
hematoxylin solution. The number of migrated cells on the
lower face of the filters was counted in five fields under 100
magnification. Assays were done in triplicates.
Tube Formation Assays
In vitro formation of tubular structures was studied on
BioCoat Matrigel tissue culture plates (BD Biosciences, Bed-
ford, MA). Briefly, HUVECs were plated at 3.5 105 cells/
well in 24-well plates precoated with a solution of Matrigel
basement membrane matrix, and left untreated or exposed
to TRAIL or VEGF. After 48 hours of incubation at 37jC, the
cell 3D organization was examined under an inverted photo-
microscope and photographed (40). Each treatment was
performed in triplicate.
In vitro angiogenesis was assessed as formation of
capillary-like structures of HUVECs cocultured with matrix-
producing cells that had been UV-irradiated before plating of
primary HUVECs (TCS Biologicals, Buckingham, UK) [19].
Briefly, cultures were left untreated or stimulated with TRAIL
or VEGF, used alone or in combination, at day 3. When
indicated, PD98059 or the vehicle (0.25% DMSO), previous-
ly diluted in medium, was added to the cultures 45 minutes
before exposure to TRAIL or VEGF. Medium and treatments
were replaced every 2 to 3 days. At day 12, the cells were
fixed and HUVECs were stained using an anti–CD31 Ab
(TCS Biologicals, Buckingham, UK), according to the instruc-
tions provided with the kit. Images were captured and
analyzed. In particular, to measure the formation of the
capillary network, the number of connections between three
or more capillary-like structures and the total length of tubes
were quantified by image analysis at 40 magnification.
Four-six different fields were analyzed per well.
Western Blot Analysis
For Western blots, HUVECs were plated in 10-cm dishes
and grown at subconfluence before treatments. In order to
minimize activation by serum, HUVECs were subject to
partial fetal calf serum (FCS) reduction (to 0.5%) and com-
plete growth factor withdrawal for 18 hours prior to the
addition of TRAIL or VEGF, used alone or in combination.
Cells were harvested in lysis buffer containing 1% Triton
X-100, Pefablock (1 mM), aprotinin (10 mg/ml), pepstatin
(1 mg/ml), leupeptin (10mg/ml), NaF (10 mM), and Na3VO4
(1 mM). Protein determination was performed by Bradford
assay (Bio-Rad, Richmond, CA). Equal amounts of protein
(50 mg) for each sample were migrated in acrylamide
gels and blotted onto nitrocellulose filters. Blotted filters
were probed with antibodies for the phosphorylated ERK1/2
and p38/MAPK (all from New England Biolaboratories,
Beverly, MA). After incubation with peroxidase-conjugated
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anti–rabbit or anti–mouse IgG (Sigma), specific reactions
were revealed with the Enhanced Chemiluminescence
(ECL) Western blotting detection reagent. Membranes were
stripped by incubation in Re-Blot 1  Ab stripping solution
(Chemicon International) and reprobed for the respective
total protein kinase content or b-actin (New England Biol-
aboratories) for verifying loading evenness.
Densitometric values, expressed in arbitrary units, were
estimated by the ImageQuant software (Molecular Dynam-
ics, Piscataway, NJ). Multiple film exposures were used to
verify the linearity of the samples analyzed and avoid satu-
ration of the film.
[3H]Thymidine Incorporation
HUVECs were plated onto 96-well plates at a density of
5 103 cell/well. On the next day, the medium was changed
to endothelial cell basal medium containing 0.5% FBS and
0.1% BSA (starvation medium). The cells were then pre-
treated with PD98059 for 1 hour and incubated with TRAIL or
VEGF, used alone or in combination, for 30 hours. [3H]thy-
midine (1 mCi) was added to each well during the last 6 hours
of incubation. [3H]thymidine-labeled DNA was then mea-
sured using a Beckman (Fullerton, CA) model LS6000IC
liquid scintillation counter.
Statistical Analysis
Data were analyzed using the two-tailed, two-sample
t-test (statistical analysis software; Minitab, State College,
PA). Values of P < .05 were considered significant.
Results
TRAIL Is Expressed in Highly Vascularized Soft
Tissue Sarcomas
Having previously demonstrated that TRAIL activates
intracellular signal transduction pathways [7,8], which have
been involved in promoting angiogenesis [13,14], in the first
group of experiments, we have investigated the expression
of TRAIL in some cases of malignant mesenchymal tumors
because these tumors are often highly vascularized [15,20].
As shown in Figure 1A, the cells of a low-grade gastric
leiomyosarcoma stained negative for TRAIL and were poorly
vascularized. However, the malignant neoplastic cells of a
high-grade leiomyosarcoma showed a strong expression of
TRAIL and were characterized by prominent neovascularity.
To ascertain that TRAIL expression was not confined to
leiomyosarcomas, we have also analyzed TRAIL expression
in some cases of angiogenetic liposarcomas (Figure 1B). In
these sarcomas, a clear-cut positivity for TRAIL was noticed
in both malignant cells as well as in tumor-infiltrating lym-
phocytes and plasma cells (Figure 1B). Finally, a high
expression of TRAIL was documented also in tumors char-
acterized by tumultuous angiogenesis, such as malignant
vascular sarcomas (Kaposi’s sarcoma; Figure 1C).
TRAIL Promotes Endothelial Cell Migration and Invasion
Because angiogenesis is a tightly regulated process,
which involves the coordinated migration, differentiation,
and morphogenetic organization of endothelial cells into
new capillary structures [18], these aspects of angiogenesis
were next examined in a series of in vitro assays.
To test whether recombinant soluble TRAIL could affect
endothelial cell motility, HUVECs were incubated in a mod-
ified Boyden chamber with recombinant soluble TRAIL
(10 ng/ml). For comparison, cells were treated also with
VEGF (10 ng/ml). TRAIL significantly (P < .01) increased
HUVECmigration (Figure 2A). The increase in the number of
migrated cells detected with TRAIL (approximately two-fold)
was similar to that observed in the presence of VEGF
(2.5-fold). Interestingly, however, the simultaneous addition
of optimal concentrations of TRAIL and VEGF did not show
additive effects on endothelial cell migration (data not
shown).
To form new blood vessels, endothelial cells have to
migrate and cross basement membranes. This invasive
capacity of HUVECs in response to TRAIL was investigated
by measuring the invasion of an ECM layer. Addition of
recombinant TRAIL significantly (P < .01) increased HUVEC
invasion through ECM (Figure 2B). Again, maximal stimula-
tion, corresponding to a 1.5-fold increase in the number of
migrated cells in response to TRAIL, was similar to that
observed in response to VEGF. The specificity of these
biological effects was confirmed by preincubation of TRAIL
with TRAIL-R1-Fc (Figure 2, A and B) or TRAIL-R2-Fc (data
not shown) chimeric proteins, which completely (P < .01)
abrogated the ability of TRAIL to promote cell migration and
invasion (Figure 2, A and B), without exhibiting, by them-
selves, any effect on endothelial cell migration or invasion
(data not shown). These data demonstrate, for the first time,
that TRAIL induces endothelial cell migration and invasion
through the basement membrane. Importantly, the TRAIL
concentration used in these assays was in the range
reported to be present in the plasma of patients affected by
hematological malignancies (1–10 ng/ml) [21].
TRAIL Induces Morphological Endothelial Differentiation
To examine whether TRAIL induces morphogenetic
changes resembling capillary-like structure tube formation,
HUVECs were plated on 3D Matrigel plates. After 48 hours,
untreated endothelial cultures showed both cells with small
round shape (that remained isolated) and elongated shape,
forming connections but an incomplete network of tubes
(Figure 3A). However, cultures exposed to TRAIL (10 ng/ml)
exhibited a distinct phenotype by assuming amore elongated
shape, forming thin cords of inteconnecting cells (Figure 3A).
Similar effects were also observed with VEGF (10 ng/ml)
(Figure 3A). Morphometric quantitation of the vessel-like
structures in the 3D cultures revealed that Fc-TRAIL-R1
completely abrogated this response to TRAIL (Figure 3B).
These data demonstrate that TRAIL, like VEGF, is able to
mediate morphogenetic effects leading to differentiation into
vascular structures, which represent an obligatory step for
the sprouting of endothelial cells and tube formation.
Because tubules formed in standard Matrigel assays are
short and relatively homogeneous, the ability of TRAIL to
induce angiogenesis was further investigated by using the
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Figure 1. Expression of TRAIL in human sarcomas. Sections of sarcomas were examined immunohistochemically by using an anti –TRAIL Ab. (A) Representative
sections of leiomyosarcomas at low (LM 1) and high vascularity (LM 2) are shown. Stainings with anti –CD31 Ab to detect endothelial cells and vascular structures,
and hematoxylin and eosin (H&E) are also shown. Original magnification, 20. (B) Liposarcoma (panel a, H&E staining, 40) showing TRAIL expression in
malignant neoplastic cells (arrowhead in panel b; 40), tumor-infiltrating lymphocytes (panel c; 40), and plasma cells (arrowhead in panel c; 100). (C)
Kaposi’s sarcoma showing diffuse expression of TRAIL. Original magnification, 40.
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angiogenesis coculture assay, which appeared significantly
heterogeneous, consisting of both short and long intercon-
necting tubules that more closely resembled capillaries
(Figure 4). In this assay, vessels develop where they are
well protected (e.g., between layers of fibroblasts) and
morphogenetic processes of tubule formation occur in
HUVECs completely surrounded by stromal cells, as
in vivo. The ability of fibroblasts to support tubule formation
has been attributed to their capacity of producing consider-
able quantities of collagen, fibronectin, and other matrix
molecules [19].
To rule out the possibility that the angiogenic activity of
TRAIL might be mediated by upregulation of endogenous
VEGF, the production of VEGF released in the culture
medium was analyzed by enzyme-linked immunosorbent
assay (ELISA) in both untreated and TRAIL-treated cultures.
In HUVECs, VEGF was not detected in the culture super-
natants of both untreated and TRAIL-treated cultures ana-
lyzed up to 72 hours (data not shown). In angiogenesis
coculture assay, VEGF was endogenously produced, but
the levels were similar in untreated (256 ± 36 pg/ml) and
TRAIL-treated (240 ± 45 pg/ml) cultures.
We next performed a quantitative analysis by calculating
both the total length of tubes and the number of capillary
connections per field in cocultures left untreated or exposed
to VEGF, TRAIL, and combination of the two cytokines
(10 ng/ml each). As shown in Figure 5, the basal formation
of capillary-like structures was significantly (P < .01) in-
creased after stimulation with either TRAIL or VEGF, and
TRAIL-R1-Fc chimeric protein significantly (P < .01) inhibited
TRAIL-induced total tube length and capillary connections.
Moreover, preincubation of TRAIL with 5 mg/ml polymyxin B,
which complexes and inactivates endotoxin, did not abrogate
the angiogenetic activity of TRAIL, further indicating that
these responses to TRAIL are specific. However, the simul-
taneous addition of TRAIL + VEGF did not show any additive
or synergistic effect, and it was not statistically different from
VEGF alone (Figure 5).
TRAIL Potentiates VEGF-Induced ERK1/2 But Not p38/
MAPK Phosphorylation
The findings illustrated above suggest that TRAIL and
VEGF might compete for the same intracellular signal trans-
duction pathways. Therefore, in the next group of experi-
ments, we have investigated the effect of TRAIL and VEGF,
used alone or in combination, on mitogen-activated protein
(MAP) kinase family members, which have been involved in
different aspects of angiogenesis. Although ERK1 and ERK2
are strongly activated on stimulation of cells with mitogens
[11], p38/MAPK plays a complex role in angiogenesis by
promoting cell migration and inhibiting endothelial cell sur-
vival [21–24]. After exposure to either TRAIL or VEGF,
induction of phospho-ERK1/2 was observed starting
at 5 minutes of treatment (Figure 6A). Remarkably, the
Figure 2. Effect of TRAIL on HUVEC migration and invasion. Cell migration (A) and cell invasion (B) assays were performed in 24-well Transwell plates, as
described in Materials and Methods section. Endothelial cells were seeded in the upper compartments, whereas TRAIL or VEGF was added in the lower
compartments. For neutralization experiments, TRAIL was preincubated with TRAIL-R-Fc chimera. Cells migrated through the gelatinized membranes and ECM-
coated membranes were counted after 4 hours (A) and 48 (B) hours, respectively. Data are expressed as the number of migrated cells in 10 high-power fields and
are mean ± SD of results from four experiments each performed in triplicate. *P < .01 compared to untreated cells.
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Figure 3. Effect of TRAIL on in vitro tube formation. HUVECs were seeded into 24 wells containing 3D Matrigel in the absence and presence of TRAIL ± TRAIL-
R-Fc or VEGF. (A) Photographs (40) were taken at 48 hours of cultures. Representative images of at least five experiments with similar results are shown. (B)
Five to seven random fields were photographed and recorded, and tube length was quantified by measuring the total cell projection length and individual tubular
structure. Tubular length per field is reported as mean ± SD. *P < .01 compared to untreated cells.
Figure 4. Effect of TRAIL on the capillary-like network in a coculture angiogenesis assay. Formation of capillary-like structures of HUVECs cultured with matrix-
producing cell types was analyzed after 12 days of culture treatment as indicated. Representative example of the morphology endothelial structures was detected
after staining with anti –CD31 Ab in the in vitro angiogenesis assay. Rare capillary structures were observed in the angiogenesis assay left untreated, whereas both
TRAIL and VEGF induced a diffuse network of capillary structures. Original magnification, 10.
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simultaneous addition of TRAIL + VEGF resulted in a pro-
longed activation of ERK phosphorylation with respect to
each cytokine used alone (Figure 6A). However, although
TRAIL was unable to induce p38 phosphorylation, it de-
creased somewhat the VEGF-induced phosphorylation of
p38/MAPK (Figure 6B). Consistent with a key role of the ERK
pathway in endothelial proliferation, thymidine incorporation
assay showed that the combination of VEGF + TRAIL
showed an additive effect (P < .01) with respect to VEGF
or TRAIL used alone (Table 1). Preincubation with the cell-
permeable PD098059 compound (20 mM), a commonly used
inhibitor of the ERK pathway, completely inhibited thymidine
uptake induced by any cytokine combination (Table 1),
clearly confirming that the activity of ERK is required for
TRAIL- and VEGF-induced mitogenesis.
Moreover, PD098059 treatment strongly suppressed the
total tube length and number of tube interconnections in
control, TRAIL-treated, and VEGF-treated cocultures (Fig-
ure 7), underscoring the key role of ERK pathway in the
whole process of tube formation evaluated in the angiogen-
esis assay.
Discussion
The growth of microvessels is an integral component of
tissue remodeling during a variety of normal and patho-
logical events, such as the female reproductive cycle,
fetal development, wound healing, inflammation, diabetic
retinopathy, and tumor progression [13,14]. The way in
which vessels form is being intensively studied because
this complex morphogenetic process is very important in
medicine. Although a true understanding of the morpho-
genetic processes involved in tubule formation is still
lacking, all these angiogenic events are orchestrated by
a network of extracellular factors, including several clas-
ses of cytokines, ECM, and integrins, and by their
cognate receptors. Several cytokines have been involved
in angiogenesis and, in particular, in tumor-associated
angiogenesis [13,14]. Besides its involvement in vascular
development, VEGF has been demonstrated to play a
key role in both physiologic and tumor angiogenesis in
adult mammals [25].
It has also been shown in previous studies that some
angiogenic regulators belong to the TNF family [26]. Ligands
of this family trigger biological activities by binding and
signaling through their corresponding receptors in the TNF
receptor family. The majority of the TNF family members
mediate host defense, inflammation, and immunological
regulation, but some of these ligands also regulate endothe-
lial cell functions [26]. For instance, it has been demonstrated
that TNF-a modulates endothelial cell behavior; however, its
effects are complex. TNF-a inhibits endothelial cell growth
yet induces capillary tube formation in vitro [27,28]. It also
can be antiangiogenic in the context of solid tumors, or
angiogenic in corneal settings in vivo [27–29]. In a recent
study, we have demonstrated that TRAIL functions as an
anti–apoptotic factor for endothelial cells [7], and we have
hypothesized that TRAIL may contribute to endothelial cell
integrity by acting as a survival factor for newly formed blood
vessels.
In this study, we have demonstrated for the first time
that TRAIL induces a proangiogenic phenotype in human
endothelial cells. This phenotype includes both early (in-
crease in migration, invasion, and proliferation) and late
(differentiation into vascular cords) angiogenic events.
More importantly, TRAIL is angiogenic in a variety of
in vitro and in vivo assays to a degree comparable to
VEGF. However, the interplay between TRAIL and VEGF
appears rather complex, with TRAIL unable to potentiate
VEGF activity in most assays. In fact, TRAIL increased
VEGF-induced ERK phosphorylation and HUVEC prolifer-
ation; however, TRAIL did not potentiate VEGF-induced
p38/MAPK phosphorylation or capillary formation in the
Figure 5. Lack of additive effect of TRAIL + VEGF on the capillary-like
network in coculture angiogenesis assay. Cultures treated as indicated were
observed after 12 days and results were recorded for quantitative analysis of
the total length of tubes per field and the number of capillary connections per
field. Data are expressed as mean ± SD of results from at least five
experiments each performed in duplicate. *P < .01 compared to untreated
cells.
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Figure 6. Phosphorylation of ERK1/2 and p38/MAPK in response to TRAIL and VEGF. Quiescent HUVECs were stimulated with either TRAIL, VEGF, or VEGF +
TRAIL for 0 to 180 minutes. Cell lysates were analyzed for ERK1/2 (A) and p38/MAPK (B) activation by Western blot analysis of total and phosphorylated (P)
proteins using specific antibodies. Protein bands were quantified by densitometry, and levels of P-ERK1/2 and P-p38 were calculated for each time point, after
normalization to ERK1/2 and to p38/MAPK, respectively. Unstimulated basal expression was set as unity. Results are representative of four separate experiments.
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coculture assay. Of note, we have also demonstrated that
a clear-cut expression of TRAIL was observed in highly
vascularized soft tissue sarcomas. At the moment, we
have analyzed a small number of sarcomas; experiments
aimed to analyze a high number of tumors and a wide
variety of tumors, with the aim to quantitatively evaluate
potential correlations between microvessel density and the
levels of TRAIL expression, are ongoing.
Besides malignant sarcoma cells, TRAIL was expressed
also by tumor-infiltrating lymphocytes and plasma cells.
Similar findings were obtained by previous authors describ-
ing that TRAIL was expressed by tumor-infiltrating lympho-
cytes as well as by metastatic gastric cancer cells [30].
Although the most frequent hypothesis to explain the
expression of TRAIL by cancer cells is a strategy of
immune evasion by which TRAIL-positive malignant cells
counterattack against activated T lymphocytes [30,31], our
data suggest the alternative—not mutually exclusive—
hypothesis that TRAIL expression by cancer cells, and,
perhaps also by infiltrating lymphocytes, may play a key
role in tumor angiogenesis. Consistent with this hypothesis,
it has been shown that mouse BALB/c mammary adeno-
carcinoma cells engineered to express human TRAIL on
their membrane grow faster than the parental cell line in
both syngeneic and allogeneic mice [32]. In this respect, it
has been clearly established that any significant increase
in tumor mass must be preceded by an increase in the
vascular supply to deliver nutrients and oxygen to the
tumor. The ability of a tumor to induce angiogenesis
represents an essential step for tumor growth beyond 2 to
3 mm [13]. Consistent with a potentially important role of
TRAIL in tumor angiogenesis not confined to soft tissue
sarcomas, it has been demonstrated that all primary
astrocytic brain tumors analyzed by immunohistochemis-
try, including astrocytomas and glioblastomas, express
TRAIL protein in vivo [33,34]. Similarly, TRAIL is
expressed by a subset of lymphomas [35], malignant
plasmocytoma cells [36], and ovarian carcinomas [37], in
which TRAIL expression has been correlated to the
degree of malignancy. Therefore, although recombinant
TRAIL protein offers great promise as a cancer therapeu-
tic [38], our current demonstration that TRAIL exerts a
potent proangiogenic effect adds a cautionary note to the
prolonged treatment of cancer patients with pharmacolog-
ical concentrations of recombinant TRAIL protein or
TRAIL-expressing vectors. References
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